← Back to The Absolute Effect
Testicular Germ-Cell Tumours · Medical Oncology · Poor-prognosis relapsed/refractory GCT · HDCT

TI-CE high-dose salvage chemotherapy

Can paclitaxel/ifosfamide induction followed by high-dose carboplatin/etoposide with stem-cell rescue produce durable remission in poor-risk GCT?

Single-centre mixed-GCT cohort

Population
107

Study population as reported in the cited publication; cohort sizes and denominators are stated where available.

Evidence type
Mixed GCT · phase I/II

Not all evidence is randomized, comparative, or seminoma-specific.

Reported outcomes

Among 107 heavily pretreated patients, 54 (50%) achieved complete remission and 8 (7%) additional patients had marker-negative partial response, for a 58% favourable response rate. Five-year DFS was 48% and OS 52%.

Complete remission54/107
Favourable response62/107
5-year disease-free survival48%
5-year overall survival52%

Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.

Interpretation and limitations

This was a phase I/II cohort enriched for poor-risk, often platinum-refractory disease, not a randomized trial. High-dose treatment carries substantial hematologic toxicity and treatment-related mortality.

Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.

Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025

Primary study source

Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28:1706–1713.

Original study / PubMed / registry ↗

Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.